
Disease State: Merkel Cell Carcinoma
Background
Merkel cell carcinoma (MCC) is a rare, aggressive primary cutaneous neuroendocrine carcinoma associated with Merkel cell polyomavirus, ultraviolet exposure, advanced age, and immunosuppression. Diagnosis is often delayed, and approximately one-quarter of patients present with regional nodal disease. Despite improvements in guideline-based management, outcomes remain poor, with primary resistance to checkpoint inhibition in 40–50% of patients, recurrence in approximately 40%, and a 5-year observed survival of 69%. MCC and its treatments can substantially affect quality of life and satisfaction with care across physical, emotional, social, and financial domains. However, inconsistent outcome selection, definitions, and measurement instruments limit the evaluation of interventions, and no consensus exists on the outcomes most important to measure. Developing a core outcome set could support more consistent, patient-centered evaluation of MCC treatments.
Project Goal
We aim to develop a core outcome set by (1) identifying all current outcomes from a systematic review of literature; (2) involving other stakeholder groups such as other clinicians, and regulators to participate in identifying additional outcomes; (3) conducting Delphi consensus exercises on the identified outcomes; (4) presenting all results from the Delphi exercises during a consensus meeting to vote and agree upon a core set of outcomes important for MCC research.
Key Project Team Members
Project Leads
Murad Alam
Nour Kibbi
Lisa Zaba
Eleni Linos
Daisy Spoer
Nicole Ehrhart
Steering Committee
Murad Alam
Joseph Sobanko
Ian Maher
Todd V. Cartee
C3 Methods Partner
Jamie Kirkham
Chair
Contact
Murad Alam (m-alam@northwestern.edu)
Publications
Updated November 18, 2026
